Digest Network Come funziona
Network
/
Società
Ex
Non verificato

Exelixis, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

44 comunicati stampa

Guarda tutti i comunicati
03/12/2025
Oncologia
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Eventi
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0
06/11/2025
Biotecnologia
Salute
Oncologia
Eventi
Web e Social Network
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0
04/11/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Web e Social Network
Telefonia e Varie
Mercato azionario
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0
21/10/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0
18/10/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Industria
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0
29/08/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Mercato del lavoro
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0
27/08/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Eventi
Web e Social Network
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0
28/07/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Web e Social Network
Telefonia e Varie
Mercato azionario
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0
24/07/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0
14/07/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0